Therapeutic range of Brivaracetam, a historical observational study to define a therapeutic range

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012584

Enrollment

200

Registered

2017-06-29

Start date

2017-07-03

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G40.2 G40

Interventions

Group 1: Retrospective analysis of already available data of patients with age between 18 and 89 years and a diagnosis of epilepsy and a treatment of brivaracetam

Eligibility

Sex/Gender

All

Age

18 Years to 89 Years

Inclusion criteria

Inclusion criteria: Retrospective analysis of already available data during the period of 01.03.2016 - 15.05.2017 of patients with age between 18 and 89 years and a diagnosis of epilepsy and a treatment of brivaracetam

Exclusion criteria

Exclusion criteria: 1. Healthy volunteers 2. Data from the following patients will NOT be collected: minors, mentally disabled patients, dementia patients, pregnant women, breastfeeding or emergency patients.

Design outcomes

Primary

Measure	Time frame
The aim of the study is to find out whether a therapeutic range of brivaracetam exists by examining the following parameters: 1. Serum concentration of brivaracetam which reduces the seizure attack by at least 50% over a period of at least 3 months. 2. Serum concentration of brivaracetam which lead to a documentation of the two most common neurotoxic side effects, which are fatigue and / or dizziness.	—

Measure

Time frame

The aim of the study is to find out whether a therapeutic range of brivaracetam exists by examining the following parameters: 1. Serum concentration of brivaracetam which reduces the seizure attack by at least 50% over a period of at least 3 months. 2. Serum concentration of brivaracetam which lead to a documentation of the two most common neurotoxic side effects, which are fatigue and / or dizziness.

—

Countries

Germany

Contacts

Public ContactTassanai Intravooth

Epilepsiezentrum Kork

tintravooth@epilepsiezentrum.de07851-842272

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026